8-K: GRI Bio Secures $6.7M in Public Offering

Sentiment:

Public Offering Announcement 12 December 2025 8:30 AM

GRI Bio, Inc. commenced a public offering expected to raise approximately $6.7 million to fund operations into late 2026.

Capital raiseGRI Bio commenced a best efforts public offering of 2,603,331 shares of common stock, 8,063,336 pre-funded warrants, and 10,666,667 Series F warrants.The offering is expected to generate approximately $6.7 million in net proceeds.The capital is intended to fund working capital, product candidate development, and general corporate purposes, extending the cash runway into Q4 2026.

Summary

GRI Bio, Inc. commenced a best efforts public offering on December 11, 2025.
The offering includes 2,603,331 shares of common stock, 8,063,336 pre-funded warrants, and 10,666,667 Series F warrants.
Each share or pre-funded warrant was sold together with one Series F warrant.
The combined offering price was $0.75 for a share and Series F warrant, and $0.7499 for a pre-funded warrant and Series F warrant.
The pre-funded warrants have an exercise price of $0.0001 per share, are exercisable immediately, and expire when exercised in full.
The Series F warrants have an exercise price of $0.75 per share, are exercisable immediately, and expire on December 12, 2030.
The company expects to receive approximately $6.7 million in net proceeds from the offering, after deducting fees and expenses, but excluding proceeds from the exercise of Series F Warrants.
Proceeds will be used for working capital, product candidate development activities, and general corporate purposes.
The company believes these net proceeds, combined with its existing cash and cash equivalents, will be sufficient to fund planned operations into the fourth quarter of 2026.
The offering is anticipated to close on or about December 12, 2025.

Sentiment

Score: 7

Explanation: The successful commencement of a public offering securing approximately $6.7 million in net proceeds is a positive development for GRI Bio, as it significantly extends the company's cash runway into the fourth quarter of 2026, providing crucial funding for ongoing operations and product development. However, the offering involves dilution for existing shareholders and substantial fees to the placement agent.

Positives

Secured approximately $6.7 million in net proceeds from the public offering.
The capital raise is expected to extend the company's cash runway into the fourth quarter of 2026, providing financial stability for planned operations and product development.

Negatives

The offering involves the issuance of new shares and warrants, which will result in dilution for existing shareholders.
Significant fees and expenses are associated with the offering, including a 7.0% cash fee and a 1.0% management fee to the placement agent, along with other reimbursements and warrants to purchase 746,667 shares.

Risks

Uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all.
Risks concerning the exercise of the Series F Warrants prior to their expiration.
Risks related to the future clinical development of product candidates and the timing of any trials or milestones in connection with this development.
Estimates regarding the company's cash runway or sufficiency of its resources to support planned operations may not be accurate.

Future Outlook

GRI Bio anticipates using the net proceeds from the offering for working capital, product candidate development activities, and general corporate purposes. The company believes the capital raised, combined with existing cash, will be sufficient to fund its planned operations into the fourth quarter of 2026. The offering is expected to close on or about December 12, 2025.

Management Comments

The Company believes that the net proceeds from the Offering, together with its cash and cash equivalents, will be sufficient to fund its planned operations into the fourth quarter of 2026.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Lock-up Agreement	Company agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of certain securities for 60 days after the offering's closing date, subject to certain exceptions.	December 12, 2025 (anticipated closing date)	Aims to stabilize the stock price post-offering by limiting immediate further dilution from new issuances.
Variable Rate Transaction Restriction	Company agreed not to effect or enter into an agreement to effect any issuance of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock involving a variable rate transaction until the one-year anniversary of the offering's closing date, subject to certain exceptions.	December 12, 2025 (anticipated closing date)	Protects investors from potentially highly dilutive financing structures for a specified period.
Beneficial Ownership Limitation	Warrant holders will not have the right to exercise any portion of the Series F Warrants or Pre-Funded Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99%, as applicable, of the number of shares of Common Stock outstanding immediately after giving effect to the exercise.	December 11, 2025 (offering commencement)	Prevents any single holder from accumulating too large a stake through warrant exercise, potentially avoiding certain regulatory thresholds or control issues.

Stakeholder Impact

Shareholders will experience dilution due to the issuance of new shares and warrants. However, the capital raise provides crucial funding for future operations and product development, which could benefit long-term value.
Employees may benefit from increased job security and resources for ongoing research and development efforts due to the extended cash runway.
Potential customers/patients may see accelerated development and availability of new product candidates due to secured funding.
Creditors may view the company as having improved liquidity and reduced short-term credit risk due to the extended cash runway.

Next Steps

Anticipated closing of the offering on or about December 12, 2025.
Continued product candidate development activities.
Ongoing general corporate purposes and costs associated with being a public company.

Key Dates

Date	Description
2024-12-31	End of fiscal year for which the Annual Report on Form 10-K was filed, referenced in risk factors.
2025-12-08	Registration Statement on Form S-1 originally filed with the Securities and Exchange Commission.
2025-12-11	Date of earliest event reported; Public offering commenced; Registration Statement on Form S-1 declared effective by the SEC.
2025-12-12	Anticipated closing date of the offering; Date of signing of the report by the Chief Financial Officer; Expiration date of Series F Warrants (2030); Expiration date of Placement Agent Warrants (2030).
2026-12-31	Expected period into which the company's cash and cash equivalents, combined with net proceeds, will fund planned operations (into the fourth quarter of 2026).

Keywords

GRI Bio, public offering, common stock, warrants, capital raise, financing, biotechnology, SEC filing, 8-K, cash runway, product development, Nasdaq

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.